Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for September 2010
September 1, 2010
- ReVision's Fenretinide (RT-101) Reduced Incidence of Choroidal Neovascularization by More Than 50 Percent in Patients With Geographic Atrophy in a Phase 2b Trial
- Afferent Pharmaceuticals Presents Data Supporting Use of P2X3 Antagonists in Reducing Bone Cancer Pain
- Study shows Xarelto (rivaroxaban) offers net clinical benefit for the treatment of deep vein thrombosis compared to current standard of care
- QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuo IR
- African-Americans Have Higher Risk for Blood Clots After Receiving Drug-Coated Stent
- Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial
- Data from Mipomersen Phase 3 Trial in heFH Patients Presented at ESC
September 2, 2010
- Comparable Efficacy, Improved Safety and Lower Cost for High-Dose Bolus Dosing of Aggrastat Compared to ReoPro in STEMI Patients Undergoing Primary PCI: Three-Year Follow-Up for MULTISTRATEGY
- Rexahn Pharmaceuticals Announces Publication of New Preclinical Research Data for Novel Anticancer Compound RX-8243
- Cerus and the Swiss Red Cross Report Successful Outcome of INTERCEPT Blood System Platelet Study
- Blood Publication Shows MLN4924 Preclinical Activity in Lymphoma
- Results From Investigator-Sponsored Trials Presented at SSIEM Conference
- Most Neurologists Plan to Prescribe Oral Multiple Sclerosis Drugs, but Will Proceed with Caution
- Transdel Pharmaceuticals Presents Phase 3 Study Data on Ketotransdel at World Pain Congress in Montreal, Canada
September 3, 2010
September 7, 2010
- Progenics Pharmaceuticals to Present Preclinical Study of Novel Monoclonal Antibodies Against C. difficile at 2010 ICAAC
- Immutep announces final results in phase I/II chemoimmunotherapy trial in metastatic breast cancer
- Rexahn Announces Publication of New Preclinical Research Data for RX-8243
- Scancell Holdings Plc (?Scancell Holdings' or the ?Company') Collaboration With ImmuneRegen BioSciences® Yields Positive Results in Cancer Vaccine Studies
- First AXL1717 Clinical Data From Ongoing Phase I/II Study in Cancer Patients has Been Published
- ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders
- International Study Led by VA-Harvard Physician Yields Insight on Risks from Fatty Arteries
- Neurogenetic Pharmaceuticals Announces Studies Showing Its Proprietary Compound Reduces Brain Plaques Associated with Alzheimer's Disease
- Plexxikon Data Shows PLX4032 Selectivity Enables Substantial Pathway Inhibition and Significant Clinical Response
September 8, 2010
- YM BioSciences announces positive results from CYT997 Phase I study published in British Journal of Cancer
- Renovo - Juvista Safety Studies Following Keloid Excision Concluded Successfully
- ImmunoCellular Therapeutics Announces Long-Term Disease-Free Survival Data from Phase I Study in Glioblastoma
- Tetraphase to Present Extensive Data on Novel Broad Spectrum Antibiotic TP-434 at ICAAC
- Neuralstem Collaborator to Present Stroke Study Results at Stem Cell & Regenerative Medicine Conference
- Promedior Announces Publication of New Research Demonstrating Pentraxin-2/SAP is a Potent Inhibitor of Asthma and Asthma-Induced Lung Fibrosis
September 9, 2010
- Cempra Pharmaceuticals Presents New Data on its Next Generation Fluoroketolide, Solithromycin (CEM-101) at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
- Seaside Therapeutics Reports Positive Data from Phase 2 Study of STX209 in Autism Spectrum Disorders
- Cempra Pharmaceuticals Presents New Data on Taksta (CEM-102, sodium fusidate) at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
- Vical To Present TransVax CMV Vaccine Phase 2 Results at ICAAC and Host Concurrent Conference Call and Webcast
- Transdel Pharmaceuticals Reports Excellent Results of Initial Testing on Anti-Cellulite Product Conducted by JH Direct
- Trius Therapeutics to Present Data From Drug Development Programs at ICAAC
- Allos Therapeutics Announces Folotyn Data Presentation at the 35th ESMO Congress
- 65% of People Whose Prior Treatment for Hepatitis C Was Unsuccessful Achieved SVR (Viral Cure) with Telaprevir-Based Therapy in Phase 3 REALIZE Study
September 10, 2010
- Paratek to Present Clinical Data at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Cubist Pharmaceuticals' Antibiotic Programs Featured in 47 Presentations at 50th ICAAC
- To Reach, Perchance to Kill the Cancer: A Soliloquy From Epeius Nanotechnologies Opposes That 'Sea of Troubles'
- MAP Pharmaceuticals Reports No Difference in Pulmonary Artery Pressure Between LEVADEX and Placebo in Pharmacodynamics Trial
- Cylene to Report Recent Advances With First-in-Class CK2 Inhibitor, CX-4945, at International CK2 Conference
- QVAR Versus Fluticasone in a Real-World Study Highlights the Importance of Inhaled Corticosteroid (ICS) Choice in Achieving Asthma Control
- Updated Phase 2 Data With Flutemetamol Published in Annals of Neurology
- Opioid use to relieve pain and suffering at end of life is safe in hospital-at-home setting
September 13, 2010
- Jennerex Presents Positive Interim Data Using JX-594 and Sorafenib to Treat Liver Cancer
- Seattle Genetics Announces Phase IIb Trial of Lintuzumab (SGN-33) in Patients with Acute Myeloid Leukemia (AML) Did Not Meet Primary Endpoint
- Incyte Reaches Agreement with the FDA on a Special Protocol Assessment for the Phase III Clinical Trial of INCB18424 in Polycythemia Vera
- Tetraphase Presents New Clinical and Preclinical Data for Novel AntibioticTP-434 at 2010 ICAAC
- Trevena Presents Preclinical Data for TRV120027, a Biased AT1R Ligand, at the 14th Annual Heart Failure Society of America Meeting
- Anavex 2-73: Journal Of Psychopharmacology Publishes Anti-Amnesic And Neuroprotective Data Against Amyloid Toxicity For First Of A New Class In Alzheimer's Disease
- Rib-X Pharmaceuticals Presents Data for Radezolid Demonstrating Positive Antibacterial Activity and Ability to Overcome Common Bacterial Resistance Mechanism
- Inovio Pharmaceuticals Achieves Unprecedented T-Cell Immune Responses in Human Trial of DNA Vaccine for Cervical Dysplasia and Cancer Caused by HPV
- Forward Pharma Initiates Phase II Efficacy and Safety Trial for FP187
- Genmab Announces Results of Ofatumumab Phase II Study in Multiple Sclerosis
- Novartis International AG (CH) - Novartis Phase III study shows meningococcal B vaccine candidate could be first to provide broad coverage against deadly disease
- Kowa Announces Peretinoin Reduces Recurrence Risk of Hepatocellular Carcinoma after Curative Therapy
- Stealth Peptides Inc. Announces Clinical Phase I Results With Bendavia Demonstrating Safety And Tolerability With Highly Predictable Pharmacokinetics
- Diamyd Medical: Diamyd Reports Promising Safety Findings from Phase I Study in Chronic Pain
- Vical's TransVax CMV Vaccine Achieves Statistical Significance on Key Clinical Endpoints in Phase 2 Trial
- Rib-X Pharmaceuticals' Nobel Prize Winning Structure-based Design and Optimization Platform to be Featured in a Symposium Reviewing 50 Years of Antibiotic Drug Discovery at the 50th ICAAC Meeting
September 14, 2010
- Gentium Announces Presentation of Preclinical and Clinical Data on Defibrotide at the 33rd World Congress of International Society of Hematology
- Biotie Therapies Oyj (FI) - Biotie completes Phase I with VAP-1 antibody - BTT-1023 continues to demonstrate favourable safety profile
- Adventrx Announces 12-Month Stability Data Results for ANX-530
- TenX Biopharma Publishes Data on Phase II Peripheral T-Cell Lymphoma Trial
- Ironwood and Forest Announce Positive Linaclotide Results from Phase 3 Trial in Patients with Irritable Bowel Syndrome with Constipation
- Data from Clinical Trials Show Pluristem's Placenta-Derived Cell Therapy is Safe and Improves Quality of Life and Efficacy Measurements in Patients With Critical Limb Ischemia
- Phase II Study Showed Switching ACS-PCI Patients to Effient/aspirin from Plavix/aspirin Regimen Reduced Maximum Platelet Aggregation After One Week
- Avanir Pharmaceuticals Announces Phase III STAR Trial Results Published in Annals of Neurology
- Trius Reports New Findings on Mechanisms of Antibiotic Resistance in MRSA
- Data Published in Journal of Neuroimmunology Suggest Anti-Inflammatory Role for Lead VBL Therapeutics Compound in CNS Inflammatory Diseases
- CytoGenix, Inc. Announces Positive Results from DNA Vaccine Study for Avian Flu
- Apricus Biosciences Announces Pre-Clinical Results Showing the Ability of the NexACT Technology to Enable Rectal Delivery of Biologics
- New Task Force Report On Bisphosphonate Use And Atypical Femur Fractures In Osteoporosis Patients
- Octapharma's Drive to Prevent and Eradicate FVIII Antibody Inhibitors in Haemophilia Treatment
- First US trial of bone-marrow stem cells for heart attack patients proves safe
- Breakthrough in drug trial offers hope for heart attack patients
- Study identifies underlying dysfunction of seemingly non-critical heart condition
- InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
September 15, 2010
- BioCryst Reports Results from Two Forodesine Oncology Studies
- BioCryst to Present Peramivir Data at the 50th Annual ICAAC Meeting
- Neurocrine Announces Top-Line Results of Corticotropin Releasing Factor Antagonist GSK561679 for Treatment of Major Depressive Disorder
- Regenerative Cellular Therapy in Chronic Kidney Disease Extends Survival; Tengion Preclinical Study Published in American Journal of Physiology Renal Physiology
- Rib-X Pharmaceuticals Presents Data Supporting Delafloxacin as a Potential Best-in-class Fluoroquinolone at ICAAC
- Excelimmune Presents Preclinical Data at ICAAC Demonstrating that Human Recombinant Polyclonal Antibody Therapy Provides Protection Against MRSA
- Progenics' Humanized Monoclonal Antibodies Significantly Improve Survival in an Animal Model of C. difficile-associated Disease
- Gilead's Single-Tablet ?Quad? HIV Regimen Maintains High Viral Suppression Through 48 Weeks in Phase II Study
- Childhood Cancer Survivors Show Sustained Benefit From Common ADHD Medication
September 16, 2010
- Santhera Pharmaceuticals Holding AG (CH) - Santhera Releases Additional Clinical Data Supporting the Use of Catena in LHON
- BioCryst Reports Positive Results From A Phase 2 Study Of BCX4208 Combined with Allopurinol in Patients with Gout
- Almirall and Ironwood Announce Positive Results from a Phase 3 Trial with Linaclotide in Patients with Irritable Bowel Syndrome with Constipation
- JAK Inhibitor Provides Rapid, Durable Relief for Myelofibrosis Patients
- A Safe and Effective Drug for Morning Sickness- A Large New American Study Reports
- Gene Therapy Proves Effective in Treating Severe Heart Failure; Holds Potential to Drastically Reduce Healthcare Costs for Heart Failure Patients
- Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule
- Phase II Study Showed Switching ACS-PCI patients on maintenance clopidogrel/aspirin to prasugrel/aspirin reduced maximal platelet aggregation after one week
- Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
- RegeneRx Announces TB4 Stroke Study to be Honored at American Heart Association Scientific Sessions
- Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
- Phase I/II Data Published in New England Journal of Medicine Demonstrate that Incyte JAK Inhibitor, INCB18424, Provides Marked and Durable Clinical Benefits in Patients with Myelofibrosis, a Rare, Life-Threatening Blood Cancer
- Chimerix Antiviral CMX001 Demonstrates Positive Safety and Pharmacokinetics in 46 patients with compromised renal function
- Alzheimer's drug boosts perceptual learning in healthy adults
- Neuralstem Stem Cells Survive and Differentiate Into Neurons in Rats With Stroke
- Novartis International AG (CH) - Novartis JAK inhibitor provides marked and durable clinical benefits in patients with myelofibrosis, a rare, life-threatening blood cancer
September 17, 2010
- Aradigm Presents Results Supporting Once-Daily Dosing With Its Inhaled Liposomal Ciprofloxacin Formulations at the 2010 European Respiratory Society (ERS) Annual Congress
- Data to Be Presented at ERS Conference Highlights Potential for Denufosol to Benefit Cystic Fibrosis Patients on Minimal Pharmacotherapy
- Amorfix Life Sciences Announces Publication Of A4 Data In Prestigious Journal Of Alzheimer's Disease And Provides Update On Management Changes
- Clinical Study of TT-223 in Combination With a GLP-1 Analogue Does Not Meet Study Efficacy Endpoints
- CytoGenix, Inc. Initiates Ferret Testing Expecting Positive Results for Avian Flu Vaccine Study
- BYETTA and BYDUREON to be Featured in More Than a Dozen Study Presentations at EASD 2010
September 20, 2010
- Chelsea Therapeutics Reports Phase III Trial of Northera Met Primary Endpoint and Achieved Highly Significant Symptomatic Benefits in Neurogenic Orthostatic Hypotension
- 24-Week Phase 3 Study Found Investigational Drug Dapagliflozin Improved Glycosylated Hemoglobin (HbA1c) When Added to Glimepiride in Adults with Type 2 Diabetes Mellitus
- Daxas (roflumilast) data analysis shows reduction in harmful lung attacks
- Potential First-in-Class Compound, Reveals New Approach to the Treatment of Pain (D3)
- Ablynx Reports Positive Phase I Data For Its Anti-RANKL Nanobody
- Novartis International AG (CH) - Novartis study shows Onbrez Breezhaler is superior to salmeterol in reducing breathlessness for patients with COPD
- Sanofi-aventis: Adding Lantus to Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar in Patients With Type 2 Diabetes
- Zealand Pharma (DK) - Positive Study Findings from Lixisenatide in First Phase III GetGoal Trial for Type 2 Diabetes
- Sanofi-aventis: Investigational Compound Once-Daily Lixisenatide Demonstrated Significant Improvement in Glucose Control in Patients With Type 2...
- Targeted Therapy Substantially Decreases Progression Rate in Patients with an Aggressive Form of Thyroid Cancer, Mayo Clinic Reports
- Scientific Conference Presents Latest News in Lyme Research
September 21, 2010
- New Long-Term Data on QNEXA Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years
- Rexahn Pharmaceuticals Announces Publication of Study on Neuroprotective Effects of Clavulanic Acid
- ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
- MSD?s 'Januvia' (sitagliptin) Offered Comparable Blood Sugar Reductions to the Sulphonylurea, Glimepiride
- Botulinum Toxin May Offer Temporary Drooling Relief in Children With Neurological Disorders
- Oral Laquinimod Demonstrated Sustained Efficacy and Safety in Patients with Multiple Sclerosis
- Apricus Bio Announces Confirmatory Results Qualifying NexACT as an Anti-Microbial Preservative
- Hybrigenics unveils final results of inecalcitol Phase IIa clinical study in hormone-refractory prostate cancer
- Cytos Biotechnology Presents Novel Toll-Like Receptor 9 Agonist CYT003-QbG10 for the Treatment of Allergic Asthma at the 2010 Annual Conference of the European Respiratory Society
- Data From Landmark Study Evaluating Gender Differences in Response to an HIV Therapy Published in Annals of Internal Medicine
September 22, 2010
- Boehringer Ingelheim Presents New Phase III Data Evaluating Linagliptin in People with Type 2 Diabetes
- GSK and Theravance announce combination ICS/LABA Phase II results in the Relovair development programme
- Medtronic's Resolute Drug-Eluting Stent Shows Strong Performance in Second ?All Comers' Study
- NeoStem to Present its Autologous Adult Stem Cell VSEL Technology for the Treatment of Battlefield Wounds at The USU-HJF Military Medicine Symposium in Washington DC, September 23, 2010
- Generex Presents Abstract at EASD Annual Meeting
- Stentys Self-Apposing Stent Proves Superior to Conventional Treatment of Acute Myocardial Infarction
- Clinical Update on Tamaris Phase III Trial for NV1FGF
- Results of Linjeta Study Versus Insulin Lispro Reported Today in Platform Presentation at EASD Annual Meeting
- ProtAffin AG Announces Preclinical Data in COPD for Lead Product PA401
- Landmark Report Reveals Massive Global Cost of Alzheimer's: 1% of Global GDP - and Growing
- Interleukin Genetics, Inc. and the University of North Carolina at Chapel Hill Announce Key Genetic Findings from Clinical Study on Osteoarthritis that are Predictive of Disease Progression
- Celsion Announces ThermoDox Abstract Accepted at the 2010 Breast Cancer Symposium
- Liquidia Technologies to Present Data at Evolution of Next-Generation Sequencing Conference
- Economic Model Presented at TCT 2010 Suggests That the Use of CYPHER Drug Eluting Stent May Result in Substantial Cost Savings When Compared to Other Drug Eluting Stents
September 23, 2010
- Tolerx Presents Research at European Diabetes Meeting and Enrolls First Patient in Europe in the DEFEND-2 Phase 3 Clinical Study in Type 1 Diabetes
- Tolerx Presents Baseline Data from DEFEND-1 Study Demonstrating that More Convenient Fasting C-Peptide Test Yields Comparable Results to Standard Diagnostic Test for Type 1 Diabetes
- ProtoKinetix in Partnership Discussions with Diabetes Specific Foundations and Research Organizations
- Zalicus Presents Data on Oncology Programs at Targeted Cancer Therapies World Europe 2010
- Biovest to Exhibit at Lymphoma Research Foundation's Annual Educational Forum; Personalized Cancer Vaccine Study Expert Scheduled to Present
- Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients
- Angiotech Announces Long-Term Data Show Advantages For Taxus Liberté Stent In Small Vessels And Long Lesions
- Data shows promise for injection-free diabetes treatment
- Novartis Drug SOM230 is First Medical Therapy to Show Efficacy in a Phase III Trial in Cushing's Disease, a Debilitating Hormonal Disorder
- VIVUS Announces QNEXA Presentations at the European Association for the Study of Diabetes (EASD) Annual Meeting
- OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
- Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD
- Long-Term Data Show Advantages for TAXUS Liberte Stent in Small Vessels and Long Lesions
September 24, 2010
- OrbusNeich's Genous Bio-engineered R stent Shows Favorable Safety Profile and Clinical Outcomes in Combination with Paclitaxel-Coated Balloon for De Novo Coronary Artery Disease
- 52-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus
- Yaupon Announces Positive Results from Pivotal Study of Its Proprietary Topical Mechlorethamine Gel; A Potential Treatment for Early-Stage Cutaneous T-cell Lymphoma
- Movetis starts phase III clinical trial with prucalopride in male patients with chronic constipation
- Publication of Phase I/II trial of NGR-hTNF in combination therapy for the treatment of colorectal cancer by the Annals of Oncology
- Angiotech Pharmaceuticals And Partner Athersys Announce Updated Results From Phase I Study Of Multistem In Heart Attack Patients
- Results From Argos Therapeutics' Arcelis Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
- Inovio Invited to Present at International Vaccine Conferences
- Biodel Reports Research Progress in Poster Session on Short-Acting Insulins at 46th EASD Annual Meeting
- Abbott's XIENCE V Shows Outstanding Two-Year Clinical Results Versus TAXUS in Key Safety and Efficacy Measures in SPIRIT IV Trial
- Angiotech Announces That Cook Medical's Zilver Ptx Drug-Eluting Stent Meets Its Primary Endpoint In A 479-Patient, Multi-Center, Pivotal Clinical Triala
September 25, 2010
- Seattle Genetics to Host Conference Call and Webcast on September 27, 2010 Regarding Top-line Data from Brentuximab Vedotin (SGN-35) Pivotal Hodgkin Lymphoma Clinical Trial
- Clinical Data, Inc. Presents Data from Phase I Studies of Stedivaze Demonstrating Safety and Tolerability in Patients with Asthma and COPD
September 27, 2010
- GeoVax to Present at Aids Vaccine 2010 Conference in Atlanta
- Seattle Genetics and Millennium Announce Positive Top-Line Brentuximab Vedotin (SGN-35) Data from Pivotal Trial in Relapsed and Refractory Hodgkin Lymphoma
- Angiotech Announces Three Year Data From The Horizons-Ami Trial Provides Superior Outcomes With Boston Scientific Corporation's Taxus Drug-Eluting Stent In Heart Attack Patients
- Angiomax/Angiox (Bivalirudin) Reduced Cardiac Mortality by 44%; Reduced Overall Mortality by 25% in Severe Heart Attack Patients Following Angioplasty
- Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients With Chronic Low Back Pain
- Angiotech Announces That Cook Medical's Zilver Ptx Drug-Eluting Stent Meets Its Primary Endpoint In A 479-Patient, Multi-Center, Pivotal Clinical Trial
- Safety and Tolerability of Regadenoson in Patients With Asthma or COPD
- ISTA Pharmaceuticals Highlights Clinical Data from REMURA Phase 2 Study Presented at the 6th International Conference on the Tear Film & Ocular Surface
- Abbott's XIENCE V Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial
- Results of Zibotentan Phase III Trial In Castration Resistant Prostate Cancer
- CONSCIOUS-2 Study With Clazosentan Does Not Meet Primary Endpoint
- Lexiscan (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010
- Enobia Reports Positive Results For Phase II Trial of ENB-0040 in Juvenile Hypophosphatasia
- Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
- Predicting Cardiac and All-Cause Mortality Using 123I-mIBG Myocardial Scintigraphy in Heart Failure Patients
- Results of Successful Trial for Alzheimer Patients Applying Novel, Non-Invasive Technology to Be Revealed at Geneva Conference
- Data from Multiple Clinical Trials of OrbusNeich's Genous Bio-engineered R Stent Demonstrate Safety and Effectiveness Across Challenging Patient Subsets as Presented at TCT 2010
- HORIZONS-AMI Trial Provides Superior Outcomes Data at Three Years with TAXUS Drug-Eluting Stent in Heart Attack Patients
- Cerus' INTERCEPT Platelet System Succeeds in 3-Year French Study
- PROLOR Biotech's Longer-Acting Human Growth Hormone Data Selected for Presentation at 5th International Congress Of The Growth Hormone Research Society and IGF Society
September 28, 2010
- Mayo Collaboration Finds Source of Breast Drug Side Effect
- Alzheimer's Fights Brain Cancer
- NeuroDerm Presents at the 14th European Federation of Neurological Societies Meeting and the 2nd World Parkinson's Congress
- Aeterna Zentaris: Poster on Diagnostic Use of Oral Synthetic Growth Hormone Secretagogue/Ghrelin Receptor Agonist, AEZS-130 (Macimorelin, Solorel) to be Presented at Upcoming 5th International Congress of the GRS-IGF Society in New York
- XenoPort Announces Presentation of New Data for XP21279 at World Parkinson Congress
- New Discovery Targets Cytomegalovirus (CMV)
September 29, 2010
- Cypher Sirolimus Drug-Eluting Stent Remains Unsurpassed In Terms Of Safety And Efficacy
- Alnylam Publishes Results from Phase IIa Study of ALN-RSV01 in the Treatment of Respiratory Syncytial Virus Infection in Lung Transplant Patients
- Synosia Presents Data from Clinical Trial of SYN-118 As A New Treatment For Parkinson's Disease
- Blood Publishes Pre-Clinical Data on GlycoMimetics, Inc. Lead Compound in Sickle Cell Disease Model
- Varying CRP Levels in Ethnic Groups May Affect Statin Eligibility, Heart Risk Prediction
- New Study Demonstrates Ready-to Use Cardene I.V. More Effective than Labetalol for Immediate Control of Blood Pressure in Emergency Room Patients
- ZymoGenetics Reports Favorable Survival Data from IL-21 Phase 2a Clinical Trial in Melanoma
- Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
- Nuon Therapeutics Announces Gout Program Study Results to Be Presented at the American College of Rheumatology
September 30, 2010
- Dicerna Pharmaceuticals to Present at Upcoming Conferences in October
- New Study Shows Zyclara (Imiquimod) Cream, 3.75% Significantly Improves Efficacy of Cryosurgery in Reducing Actinic Keratoses
- Addition Of Immunotherapy Boosts Pediatric Cancer Survival
- Juvaris BioTherapeutics Announces Publication of Preclinical Anti-Leukemic Effects of JVRS-100 Immunotherapy
- Phase II study finds tanezumab reduces osteoarthritis knee pain
- Advanced Cell Technology Provides Update on Its Myoblast Program
- Santarus and Cosmo Announce Positive Top-Line Results in U.S. Phase III Clinical Study Evaluating Budesonide MMX in Ulcerative Colitis
- Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin
- Neupro (Rotigotine) Provided Clinically Relevant Improvements in Health-Related Quality of Life for People with Parkinson's Disease
- New Therapy Boosts Cure Rate by 20% in a Deadly Childhood Cancer
